Sigma Planning Corp Has $4.06 Million Position in Bristol Myers Squibb Company (NYSE:BMY)

Sigma Planning Corp boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 20.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 66,619 shares of the biopharmaceutical company's stock after buying an additional 11,416 shares during the quarter. Sigma Planning Corp's holdings in Bristol Myers Squibb were worth $4,063,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Pinney & Scofield Inc. acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $26,000. Transce3nd LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $28,000. Global Wealth Strategies & Associates grew its position in shares of Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Bristol Myers Squibb in the first quarter valued at about $31,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

BMY traded up $0.73 during midday trading on Wednesday, reaching $47.16. 13,248,827 shares of the company's stock were exchanged, compared to its average volume of 12,808,637. The firm has a market capitalization of $95.98 billion, a price-to-earnings ratio of 17.66, a price-to-earnings-growth ratio of 2.39 and a beta of 0.36. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. Bristol Myers Squibb Company has a one year low of $41.20 and a one year high of $63.33. The business has a 50-day simple moving average of $47.42 and a two-hundred day simple moving average of $53.06.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company's revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the business posted ($4.40) earnings per share. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.26%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is 92.88%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BMY. Jefferies Financial Group lowered their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Finally, Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $57.69.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.